Abstract Background: Infants with congenital heart disease (CHD) frequently undergo surgery during their first year of life. Infants undergoing CHD surgery experience systemic inflammation and haemodilution that can deplete circulating..
Read More
Abstract Vilobelimab, a first-in-class, human–mouse chimeric immunoglobulin G4 (IgG4) kappa monoclonal antibody, targets human complement component 5a (C5a) in plasma. Unlike upstream complement inhibitors, vilobelimab does not inhibit the generation..
Read More
Abstract The present study aimed to assess the changes in the immunological parameters of patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). The serum or plasma samples of patients were..
Read More